8-K: Ocular Therapeutix Announces Positive Updates to AXPAXLI Wet AMD Program and Reports Q4 and Full Year 2024 Financial Results

Ocular Therapeutix reports key updates to its AXPAXLI registrational program for wet AMD, including FDA agreement on re-dosing and a reduced SOL-R trial size, alongside Q4 and full year 2024 financial results.

Summary

• Ocular Therapeutix announced financial results for the fourth quarter and full year ended December 31, 2024, and provided updates on its AXPAXLI program for wet AMD.
• The FDA approved an amendment to the SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76.
• Topline data from the SOL-1 trial is now expected in 1Q 2026 due to the masking requirement until Week 52 for re-dosing.
• The inclusion of re-dosing in SOL-1 allows for a reduction in the SOL-R trial size to 555 subjects, potentially accelerating registration timelines.
• The company's cash balance was $392.1 million as of December 31, 2024, expected to fund operations into 2028, and the company does not intend to raise additional capital this year.
• FDA feedback on clinical trial design for AXPAXLI in NPDR and DME is expected in 1H 2025.
• Total net revenue for the fourth quarter of 2024 was $17.1 million, a 15.4% increase over the comparable quarter in 2023.
• Total net revenue for the full year 2024 was $63.7 million, an increase of 9.0% compared to 2023.
• The net loss for the fourth quarter of 2024 was $(48.4) million, or $(0.29) per share.
• The company reported a net loss of $(193.5) million, or a loss of $(1.22) per share, for the year ended December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the FDA agreement, reduced trial size, strong cash position, and revenue growth, but tempered by the delayed topline data and net loss.

Positives

• FDA approval of the amendment to the SOL-1 SPA to include AXPAXLI re-dosing is a positive regulatory development.
• The reduction in the SOL-R trial size can lead to accelerated timelines and cost savings.
• The strong cash position of $392.1 million provides financial stability and runway into 2028.
• The company's intention not to raise additional capital this year is a positive signal to investors.
• The increase in total net revenue for both Q4 and the full year indicates growth in the company's commercial operations.

Negatives

• The delay in topline data from the SOL-1 trial to 1Q 2026 could push back potential regulatory submissions.
• The net loss of $(193.5) million for the year ended December 31, 2024, is significant, although it reflects increased R&D spending.
• Increased R&D expenses for the fourth quarter of 2024 were $41.0 million versus $16.2 million for the comparable quarter in 2023.

Risks

• The success of AXPAXLI is dependent on positive results from the SOL-1 and SOL-R trials.
• Regulatory approval is not guaranteed, even with positive trial results.
• The company's future performance depends on its ability to successfully commercialize AXPAXLI and other product candidates.
• Clinical trial activities for AXPAXLI in NPDR and DME could impact the cash runway.
• The company's existing indebtedness could impact financial flexibility.

Future Outlook

The company expects its current cash balance to fund operations into 2028 and does not intend to raise additional capital this year. They anticipate FDA feedback on clinical trial design for AXPAXLI in NPDR and DME in 1H 2025 and expect topline data from the SOL-1 trial in 1Q 2026.

Management Comments

• Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer, stated that 2024 was a transformative year and that AXPAXLI has the potential to disrupt the wet AMD treatment paradigm.
• Dr. Dugel mentioned that the company is executing with speed and precision and that the updates are designed to accelerate the path to NDA submission.
• Dr. Dugel concluded that the company has started 2025 with confidence and conviction, backed by a world-class team, a groundbreaking asset, strong trial momentum, and a substantial capital position.
• Nadia K. Waheed, MD, Chief Medical Officer, stated that the SOL program was designed to answer the most relevant questions about durability, flexibility, and repeatability of AXPAXLI in wet AMD.

Industry Context

The announcement is relevant to the broader ophthalmology and biopharmaceutical industries, particularly companies focused on retinal diseases like wet AMD, NPDR, and DME. Competitors in the wet AMD space include companies marketing or developing anti-VEGF therapies such as aflibercept (Eylea) from Regeneron and Bayer, brolucizumab (Beovu) from Novartis, and faricimab (Vabysmo) from Roche. The potential for AXPAXLI to offer a more durable treatment option could provide a competitive advantage.

Comparison to Industry Standards

• The non-inferiority margin of -4.5 letters of mean BCVA in the SOL-R trial is in line with FDA draft guidance for wet AMD trials.
• The inclusion of an aflibercept (8 mg) masking comparator arm in SOL-R aligns with the FDA's recommendations for clinical trial design.
• The company's cash runway into 2028 is a strong indicator of financial stability compared to other biotech companies in the space.
• The reduction in SOL-R trial size to 555 subjects is a strategic move to accelerate timelines, which is a common goal in the competitive pharmaceutical industry.

Stakeholder Impact

• Shareholders may be positively impacted by the potential for accelerated registration timelines and the company's strong financial position.
• Patients with wet AMD may benefit from the potential for a more durable treatment option.
• Employees may be positively impacted by the company's growth and financial stability.

Next Steps

• The company will continue to execute the SOL-1 and SOL-R trials.
• The company will seek FDA feedback on clinical trial design for AXPAXLI in NPDR and DME.
• The company will prepare for potential commercialization of AXPAXLI.
• The company will host a conference call and webcast to discuss the results.

Key Dates